228 related articles for article (PubMed ID: 9517632)
1. The circulating common gamma chain (CD132) in inflammatory bowel disease.
Nielsen OH; Kirman I; Johnson K; Giedlin M; Ciardelli T
Am J Gastroenterol; 1998 Mar; 93(3):323-8. PubMed ID: 9517632
[TBL] [Abstract][Full Text] [Related]
2. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
Nielsen OH; Ciardelli T; Wu Z; Langholz E; Kirman I
Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
[TBL] [Abstract][Full Text] [Related]
3. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
Straub RH; Vogl D; Gross V; Lang B; Schölmerich J; Andus T
Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
[TBL] [Abstract][Full Text] [Related]
4. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
[TBL] [Abstract][Full Text] [Related]
5. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
Mokrowiecka A; Gasiorowska A; Małecka-Panas E
Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
[TBL] [Abstract][Full Text] [Related]
6. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
7. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases.
Ludwiczek O; Kaser A; Tilg H
Int J Colorectal Dis; 2003 Mar; 18(2):142-7. PubMed ID: 12548417
[TBL] [Abstract][Full Text] [Related]
9. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Bansi DS; Chapman RW; Fleming KA
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
[TBL] [Abstract][Full Text] [Related]
11. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
[TBL] [Abstract][Full Text] [Related]
12. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells.
Baumgart DC; Metzke D; Schmitz J; Scheffold A; Sturm A; Wiedenmann B; Dignass AU
Gut; 2005 Feb; 54(2):228-36. PubMed ID: 15647187
[TBL] [Abstract][Full Text] [Related]
13. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease.
Andoh A; Tsujikawa T; Hata K; Araki Y; Kitoh K; Sasaki M; Yoshida T; Fujiyama Y
Am J Gastroenterol; 2005 Sep; 100(9):2042-8. PubMed ID: 16128950
[TBL] [Abstract][Full Text] [Related]
14. Increased numbers of interleukin-15-expressing cells in active ulcerative colitis.
Kirman I; Nielsen OH
Am J Gastroenterol; 1996 Sep; 91(9):1789-94. PubMed ID: 8792700
[TBL] [Abstract][Full Text] [Related]
15. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
16. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens.
Sugi K; Saitoh O; Matsuse R; Tabata K; Uchida K; Kojima K; Nakagawa K; Tanaka S; Teranishi T; Hirata I; Katsu K
Am J Gastroenterol; 1999 May; 94(5):1304-12. PubMed ID: 10235211
[TBL] [Abstract][Full Text] [Related]
17. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
18. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease.
Cantor MJ; Nickerson P; Bernstein CN
Am J Gastroenterol; 2005 May; 100(5):1134-42. PubMed ID: 15842590
[TBL] [Abstract][Full Text] [Related]
19. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease.
Koutroubakis IE; Xidakis C; Karmiris K; Sfiridaki A; Kandidaki E; Kouroumalis EA
Eur J Clin Invest; 2006 Feb; 36(2):127-32. PubMed ID: 16436095
[TBL] [Abstract][Full Text] [Related]
20. Serum tumor necrosis factor activity in inflammatory bowel disease.
Maeda M; Watanabe N; Neda H; Yamauchi N; Okamoto T; Sasaki H; Tsuji Y; Akiyama S; Tsuji N; Niitsu Y
Immunopharmacol Immunotoxicol; 1992; 14(3):451-61. PubMed ID: 1517530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
